Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G Rose

Showing results (91-100 of 201) with videos related to

Pageof 21
Sort By:
Gynecologic Oncology Reports|December 9, 2020
Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer populationMichelle L Kuznicki, Carrie Bennett, Meng Yao, et al.
Immunotherapy|August 23, 2021
Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancersYing Ni, Ahmed Soliman, Amy Joehlin-Price, et al.
Gynecologic Oncology Reports|March 17, 2025
Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective studyJohanna Kelley, Meng Yao, Danielle Chau, et al.
Gynecologic Oncology|April 26, 2003
Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyPeter G Rose, John A Blessing, Richard E Buller, et al.
Gynecologic Oncology|August 8, 2006
Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology GroupPaul A DiSilvestro, Joan L Walker, Astrid Morrison, et al.
Gynecologic Oncology|January 28, 2021
Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancerLaura M Chambers, Chad M Michener, Peter G Rose, et al.
American Journal of Obstetrics and Gynecology|May 18, 2020
Use of prophylactic closed incision negative pressure therapy is associated with reduced surgical site infections in gynecologic oncology patients undergoing laparotomyLaura Moulton Chambers, Molly Morton, Erika Lampert, et al.
Frontiers in Oncology|August 12, 2021
Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcinoma of the Cervix - A Longitudinal StudyAta Abbas, Morgan Gruner, Jennifer Karohl, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 19, 2019
Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomesMariam AlHilli, Paul Elson, Lisa Rybicki, et al.
Gynecologic Oncology|April 9, 2008
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyMartee L Hensley, John A Blessing, Koen Degeest, et al.
Pageof 21

Showing results (91-100 of 201) with videos related to

Sort By:
Pageof 21
Gynecologic Oncology Reports|December 9, 2020
Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer populationMichelle L Kuznicki, Carrie Bennett, Meng Yao, et al.
Immunotherapy|August 23, 2021
Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancersYing Ni, Ahmed Soliman, Amy Joehlin-Price, et al.
Gynecologic Oncology Reports|March 17, 2025
Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective studyJohanna Kelley, Meng Yao, Danielle Chau, et al.
Gynecologic Oncology|April 26, 2003
Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyPeter G Rose, John A Blessing, Richard E Buller, et al.
Gynecologic Oncology|August 8, 2006
Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology GroupPaul A DiSilvestro, Joan L Walker, Astrid Morrison, et al.
Gynecologic Oncology|January 28, 2021
Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancerLaura M Chambers, Chad M Michener, Peter G Rose, et al.
American Journal of Obstetrics and Gynecology|May 18, 2020
Use of prophylactic closed incision negative pressure therapy is associated with reduced surgical site infections in gynecologic oncology patients undergoing laparotomyLaura Moulton Chambers, Molly Morton, Erika Lampert, et al.
Frontiers in Oncology|August 12, 2021
Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcinoma of the Cervix - A Longitudinal StudyAta Abbas, Morgan Gruner, Jennifer Karohl, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 19, 2019
Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomesMariam AlHilli, Paul Elson, Lisa Rybicki, et al.
Gynecologic Oncology|April 9, 2008
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyMartee L Hensley, John A Blessing, Koen Degeest, et al.
Pageof 21